 Home > Medical News > Medicines Company News > Guangshengtang anti-new coronavirus oral small molecule class of innovative drugs Taizhongding completed and obtained the clinical study (IIT) summary report initiated by the investigator

Guangshengtang anti-new coronavirus oral small molecule class of innovative drugs Taizhongding completed and obtained the clinical study (IIT) summary report initiated by the investigator

 Last Update: 2023-02-01
 Source: Internet
 Author: User

Tags

enbrel drug class

drug interaction tool

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In order to evaluate the efficacy and safety of GST-HG171 (proposed Chinese generic name "Taiatevir") combined with ritonavir (collectively referred to as "Taizhongding") in patients with the new crown of Fujian Guangsheng Zhonglin Biotechnology Co.
, Ltd.
, a subsidiary of Fujian Guangshengtang Pharmaceutical Co.
, Ltd.
, an innovative drug holding subsidiary of Fujian Guangsheng Tang Pharmaceutical Co.
, Ltd.
, the investigators initiated clinical trials (IIT) in the First Affiliated Hospital of Guangzhou Medical University and the Third People's Hospital of Shenzhen.
All subjects have been enrolled and clinically observed have been completed, and a clinical study summary report
has been obtained recently.
The results of the study show that Taizonidine (Taiatevir GST-HG171 tablets/ritonavir tablets) has superior anti-new coronavirus efficacy, and the nucleic acid conversion time of new crown patients is significantly better than that of the positive control Paxlovid and placebo control, and the safety and tolerability are good, which achieves the expected purpose of the trial and provides important supporting evidence for the later drug launch, which is a major progress
in the company's new crown innovative drug research and development.
Under the guidance of experts from the National Drug Review Center, the company has fully launched the phase II.
/III.
key registration clinical research of Taizhongding, and is currently recruiting subjects in more than 30 centers across the country, striving to fulfill corporate responsibility for epidemic prevention
.

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.